ATR 1072 in Participants With PRKAG2 Syndrome

Starting soon · Phase 1/Phase 2

Conditions studied: Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome

In brief

ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.

Key facts

Study ID

NCT07738107

Run by

Atrium Therapeutics

People needed

37

Starts

2026-10-01

Expected to finish

2028-10-01

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults 18 to 65 years of age.
• Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.
• Clinical manifestations consistent with PRKAG2 Syndrome.
• Able and willing to comply with study procedures.
• Able and willing to undergo endomyocardial biopsy procedures (Part A)

You may not qualify if…

• Pregnancy or breastfeeding.
• Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.
• NYHA Class IV heart failure or left ventricular ejection fraction <45%.
• Recent clinically significant cardiovascular events or procedures.
• Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods.
• Any condition that, in the investigator's

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.